Shopping Cart
Remove All
Your shopping cart is currently empty
Synonyms: BMS066, BMS 066


| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $548 | - | In Stock | |
| 5 mg | $1,650 | - | In Stock | |
| 10 mg | $2,230 | - | In Stock | |
| 25 mg | $3,330 | - | In Stock | |
| 50 mg | $4,390 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $1,670 | - | In Stock |
| Description | BMS-066 is an IKKβ/Tyk2 pseudokinase inhibitor with IC50 values of 9 nM and 72 nM, respectively. BMS-066 is used in kinase signaling research systems to investigate NF-κB pathway regulation, JAK/STAT-associated signaling modulation, and inflammatory response control in cellular disease models. |
| Targets & IC50 | IKKβ:9 nM, TYK2:72 nM |
| In vitro | BMS-066 demonstrates significant inhibition of IKKβ-catalyzed phosphorylation in vitro, with a potent IC50 of 9 nM, exhibiting over 500-fold selectivity towards IKKβ compared to IKKα. In assays with six kinases that were more than 75% inhibited at 10 μM, BMS-066 displayed over 30-fold selectivity over the next most susceptible kinase (Brk), indicating its specificity. Additionally, BMS-066 showed IC50 values of 72 and 1020 nM in Tyk2 pseudokinase domain probe displacement and IL-23-stimulated reporter assays respectively. A broader selectivity assessment against 155 kinases at 10 μM revealed that only six were inhibited more than 75%, confirming BMS-066's greater than 400-fold selectivity for IKKβ over 95% of the kinases tested. BMS-066 also effectively inhibits LPS-stimulated cytokine production in human peripheral blood mononuclear cells (PBMCs) at both protein and mRNA levels, with similar IC50 values around 200 nM, and it inhibits IKKβ-mediated phosphorylation of IkBα in LPS-stimulated cells with a comparable efficacy. |
| In vivo | Method: Dose-dependent evaluation of BMS-066 was performed in an experimental arthritis model using histological analysis, bone density measurement, and microcomputed tomography. Result: Low-dose BMS-066 (5 mg/kg) reduced inflammation and produced more focal and less severe bone resorption compared with control. At 10 mg/kg, joints were normal or showed minimal inflammation and bone resorption. Bone density and microCT analysis showed dose-dependent protection against bone loss, pitting, porous bone formation, and bone fusion. Serum exposure indicated approximately 3 h coverage of mouse whole-blood IC50 after a single dose, and IKKβ inhibition reduced TNF-α and IL-1β production in tissues. |
| Synonyms | BMS066, BMS 066 |
| Molecular Weight | 379.42 |
| Formula | C19H21N7O2 |
| Cas No. | 914946-88-6 |
| Smiles | O=C(NCC1=NC(=CC=C1)C=2N=C3NC(NC)=C4N=CN(C4=C3C2)C)COC |
| Relative Density. | 1.43 g/cm3 (Predicted) |
| Storage | Keep away from moisture,Store at low temperature Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 80 mg/mL (210.85 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density. | ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 µL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 µL Tween 80 and mix well until fully clarified.
3) Add 450 µL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.